Abstract
Background High-grade gliomas are fatal with universally poor prognosis. Initiation of effective cancer immune responses requires functional immune cells, particularly afferent antigen-presenting cells, which are typically absent from the brain parenchyma. To overcome this limitation, two adenoviral vectors expressing HSV1-TK and Flt3L were combined to target human gliomas. This first-in-human trial assessed safety, cytotoxicity, and recruitment of immune cells to the brain, in support of a future phase 1b/2 clinical trial.
Methods Treatment-naïve high-grade glioma adult patients received injections of adenoviral vectors expressing HSV1-TK and Flt3L into the tumor bed, following maximal safe resection, at six escalating doses ranging from a total of 1.1×1010 to a maximum of 2×1011 viral particles. This was followed by two 14-day courses of Valacyclovir and standard upfront chemoradiation. Key inclusion criteria were age between 18 to 75, KPS≥70, and treatment-naïve possible high-grade glioma amenable to gross total resection. Patients were consented pre-operatively, and definitive enrollment occurred intraoperatively upon pathology confirmation of malignant glioma.
Findings The treatment was well-tolerated without dose-limiting toxicity in patients with high grade glioma (n=17) (including 3 of the Gliosarcoma variant), or Anaplastic Ependymoma (n=1). The maximal-tolerated dose was not reached. The median overall survival was 21.3 months (95%CI: 11.1, 26.1) compared to 14.6 months with standard-of-care, with seven patients surviving for >2 years, three patients surviving for >3 years, and one patient still alive 57 months after enrollment. Tissue from subsequent re-resections from eight subjects showed elevated markers for CD3+, CD8+ T cells, and plasmacytoid dendritic cells (pDCs), suggesting the potential stimulation of anti-glioma immunity. Additionally, we detected biological activity from both viral vectors: (i) an increase in serum levels of Flt3L two weeks after vector administration, and (ii) expression of HSV1-TK in neurons, astrocytes, and SOX2+ cells in brain tumor samples up to 17 months post-vector injection into the brain.
Interpretation Use of two adenoviral vectors expressing HSV1-TK and Flt3L appears to be both safe and feasible. Promising evidence from multiplex immunocytochemical analyses shows the presence of the expected immune infiltration, i.e., pDCs, along with persistent vector expression lasting up to 17 months post-injection. Moreover, the two-year survival rate of 38.8% compared to 19.6% with standard-of-care is promising, suggesting that this approach warrants further investigation in a phase 1b/2 clinical trial.
Funding Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, and The Rogel Cancer Center at The University of Michigan; clinicaltrials.gov: NCT01811992.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01811992 BB-IND14574
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT01811992
Funding Statement
Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, and The Rogel Cancer Center at The University of Michigan; clinicaltrials.gov: NCT01811992.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have obtained ethics approval from the Institutional Review Board-MED at the University of Michigan School of Medicine before enrollment (HUM00057130). The trial has been registered at ClinicalTrials.gov (NCT01811992). Prior to the initiation of the study, we obtained an Investigational New Drug (IND) from the FDA (BB-IND 14574). All patients provided pre-operative consent, and definitive enrollment occurred intraoperatively after confirming the presence of malignant glioma through Pathology examination. The most recent version of the Clinical Protocol can be accessed in the study protocol document.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
In the revised version of our manuscript, several notable changes have been made to enhance its quality and impact. Firstly, we have incorporated new clinical trial references that provide additional evidence and support for our findings. These updated references strengthen the scientific basis of our research and provide a more comprehensive overview of the topic. Secondly, we have made improvements to the figure included in the manuscript. By enhancing the figure's clarity and visual appeal, we aim to facilitate better understanding and engagement for readers. Lastly, we have reviewed and updated the text wherever corrections are required.
Data Availability
All data produced in the present work are contained in the manuscript and are also available upon reasonable request to the authors.
